OVARIAN
BGOG-ov-50
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)
Sponsor: Novocure
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Gent, Gent
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- AZ Maria Middelares, Gent
- CHU Dinant Godinne, Yvoir
- Grand Hôpital de Charleroi, Charleroi
- Imelda ziekenhuis, Bonheiden
- CHU UCL St-Luc, Bruxelles
Learn More ->
BGOG-ov-46
Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients
Sponsor: AstraZeneca
Participating sites:
- AZ Nikolaas, St-Niklaas
- AZ Damiaan, Oostende
- OLV Aalst, Aalst
- UZ Leuven, Leuven
- CHU UCL Namur, site Sainte Elisabeth, Namur
Learn More ->
BGOG-ov-44
A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Sponsor: GSK/Tesaro
Participating sites:
- UZ Leuven, Leuven
- AZ Sint-Jan Brugge, Brugge
- CHU St. Pierre, Bruxelles
- AZ Klina, Brasschaat
Learn More ->
BGOG-ov-43
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Maria Middelares, Gent
- Imelda Ziekenhuis, Bonheiden
- Grand Hôpital de Charleroi, Charleroi
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- UZ Gent, Gent
- Jessa Ziekenhuis, Hasselt
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
Learn More ->
BGOG-ov-41
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Participating sites:
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- CHU UCL Namur, site Sainte Elisabeth, Namur
- CHU UCL St. Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU de Liège, site Sart Tilman, Liège
Learn More ->
BGOG-ov-55
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Sponsor: ImmunoGen
Participating sites:
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- OLV Aalst, Aalst
- UZ Antwerpen, Antwerpen
- AZ Sint Lucas, Gent
- AZ Klina, Roeselare
Learn More ->
ENDOMETRIUM
BGOG-en-6
A Phase 3, Randomized, Double-blind, Multicenter Study Comparing TSR-042 plus Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin plus Placebo in Patients with Recurrent or Advanced Endometrial Cancer Who Had Received no Previous Systemic Anticancer therapy for Advanced or Metastatic Disease
Sponsor: GSK/Tesaro
Participating sites:
- UZ Leuven, Leuven
- CHU de Liège, site Sart Tilman, Liège
- OLV Aalst, Aalst
Learn More ->
BGOG-en-9
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- UZ Leuven, Leuven
- CHU UCL St-Luc, Bruxelles
- UZ Antwerpen, Antwerpen
- AZ Maria Middelares, Gent
- AZ Delta, Roeselare
Learn More ->
BGOG-en-10
Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer
Sponsor: AstraZeneca
Participating sites:
- UZ Leuven, Leuven
- UZ Gent, Gent
- CHU UCL St-Luc, Bruxelles
- Hôpital de Libramont, Libramont
- AZ Groeninge, Kortrijk
- AZ Sint Jan Brugge, Brugge
- Grand Hôpital de Charleroi, Charleroi
- Clinique CHC Montlégia, Liège
- Jessa Ziekenhuis, Hasselt
Learn More ->
VULVAR
CERVIX
BGOG-cx-8
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® ®-TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Sponsor: Genmab
Participating sites:
- UZ Leuven, Leuven
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU UCL St-Luc, Bruxelles
- AZ Sint-Jan Brugge, Brugge
- UZ Gent, Gent
- Hôpital de Libramont, Libramont
Learn More ->
BGOG-cx-11
A randomized, Phase 3, double-blind study of radiochemotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Sint-Lucas, Gent
- UZ Leuven, Leuven
- GZA campus Sint-Augustinus, Antwerpen
- OLV Aalst, Aalst
- CHU Ambroise Paré, Mons
- UZA, Antwerpen
Learn More ->